Dmitry Vinogradov
- Scotiabank has initiated Myriad Genetics at outperform as it’s buying and selling at a reduction to different superior diagnostics corporations and the markets it’s targeted on are below penetrated.
- The agency has a $29 worth goal (~18% upside based mostly on June 26 shut).
- Analyst Sung Ji Nam famous that whereas the corporate has undergone a big transformation over the previous few years and the rewards are actually being reaped, “we predict the corporate remains to be within the early levels of maximizing its top-line progress potential in addition to attaining sustainable profitability.”
- She added that Myriad’s focus is on molecular diagnostic checks for the oncology, girls’s well being, and pharmacogenomics sectors, a market price ~$12.9B, that’s lower than 40% penetrated on common for every. Additionally, Myriad “holds the highest three positions in six of the seven energetic product classes, and fewer than 20% of the market share is concentrated among the many high three gamers throughout the assorted markets.”
